Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8425922-B2
Publication Date
2013-04-23
Expiration Date
Abstract
This disclosure provides adjuvant compositions that are capable of modulating the immune response in a subject. These adjuvant compositions may also be used enhance the immunogenicity of antigens. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions.
Core Innovation
The invention relates to vaccine adjuvant compositions that modulate immune responses. The compositions combine free mustard oil with at least one substance selected from the group consisting of a catechin and vitamin A, and free mustard oil is described as a carrier.
In disclosed embodiments, additional components include catechin or catechin hydrate, and vitamins including vitamin A with optional vitamins E, D, and C. The adjuvant compositions may be formulated with an antigen, and the document describes vaccine contexts in which immune responses are targeted.
The document also describes mucosal administration such as intranasal and sublingual, and parenteral administration such as intramuscular. Reported outcomes include enhanced antigen-specific antibody responses and altered cytokine profiles associated with Th1, Th2, and Treg responses, including IgG1, IgG2a, and IgA responses.
Claims Coverage
The provided claim set identifies one independent claim, clm-00001, covering one inventive feature.
Composition with free mustard oil and catechin or vitamin A
A composition comprising free mustard oil and at least one substance selected from the group consisting of a catechin and vitamin A.
The inventive concept centers on pairing free mustard oil with catechin and/or vitamin A, with dependent refinements specifying particular selected components and additional named components in the composition.
Stated Advantages
Enhanced antigen-specific antibody titers.
Altered Th1/Th2/Treg cytokine profiles.
Enhanced IgG1 responses.
Elevated IgG2a responses associated with a TH1 surrogate.
Induced IgA and mucosal Ig responses.
Marked enhancement of systemic and vaginal IgG1/IgG2a/IgA responses for the described HIV gp120 formulation context.
Documented Applications
Vaccine adjuvant use with antigens, including influenza HA and HIV-1 gp120 (cn54), with reported immune responses including systemic IgG1/IgG2a and mucosal IgA.
Mucosal and parenteral administration contexts including intranasal, sublingual, and intramuscular, with reported vaginal lavage Ig responses following the described vaccination context.
Interested in licensing this patent?